Clinical trials
Advanced or Metastatic Solid Tumors clinical trials
Below are recruiting advanced or metastatic solid tumors clinical trials, each written for real people, not researchers. We’re tracking 4,772 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06196294RecruitingPhase 1
Engineered immune cells for cancers with GPC3 or mesothelin
This trial tests a new type of immune cell therapy made from your own cells (gamma-delta T cells) that are engineered to find and attack cancers that have GPC3 or mesothelin proteins. It may be an option for people with advanced cancer who have not had gene therapy before and are in generally good health.
Guangzhou, GuangdongAges 18–75 - NCT07819136RecruitingPhase 1/Phase 2
REC-7735 for people with advanced solid tumors
This study tests a new drug called REC-7735 for people with solid tumors that have a specific genetic change (PIK3CA H1047R). The drug targets this change to try to stop the cancer from growing.
Grand Rapids, MichiganAges 18 years+ - NCT06477614RecruitingPhase 1
Personalized vaccine for advanced solid tumors
This trial tests a personalized vaccine made from your own immune cells (dendritic cells) to help your body fight advanced cancer. It is for people whose cancer has not responded to other treatments.
Guanzhou, GuangdongAges 18–80 - NCT07808177RecruitingEarly Phase 1
Study of a targeted radiation drug for advanced solid tumors
This trial is testing an investigational drug called 177Lu-FAP-VG1 for people with advanced solid tumors that have stopped responding to standard therapy. The drug is a type of radiation therapy that targets a protein called FAP, which is found on many cancer cells, to try to shrink the tumor and slow the cancer's growth.
Jinan, ShandongAges 18 years+ - NCT03577197Recruiting
Breast cancer registry for advanced disease in southeast Netherlands
This trial is a cancer registry, meaning your medical information is collected and stored for people with advanced breast cancer. It can help researchers learn from real-world care patterns and outcomes across multiple hospitals in southeast Netherlands.
MaastrichtAges 18 years+ - NCT06536400RecruitingPhase 1
Testing HSK42360 for solid tumors with BRAF V600 mutation
This trial tests a new drug, HSK42360, for people with advanced solid tumors that have a specific gene change called BRAF V600. It may be an option if other treatments have stopped working.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06259552RecruitingPhase 1
Study of SPX-303 for advanced solid tumors
This trial tests a new drug called SPX-303, which is designed to help your immune system fight cancer cells. It is for people with advanced solid tumors that have not responded to other treatments.
Phoenix, ArizonaAges 18 years+ - NCT07737509Recruiting
Understanding genetic factors in advanced solid tumor treatment
This study collects and analyzes tumor samples from people with advanced solid cancers to understand why some treatments work better than others and why resistance can develop. It aims to improve future treatments for patients like you.
SuttonAges 18 years+ - NCT07734116RecruitingPhase 1/Phase 2
Nivolumab for solid tumors and epithelioid sarcoma
This trial tests a new immunotherapy drug (nivolumab) in children and adults with certain hard-to-treat solid tumors. It may help if standard treatments haven't worked or aren't an option.
Chiba, ChibaAges 12 years+ - NCT07718581RecruitingPhase 1/Phase 2
New drug for advanced solid tumors
This study tests a new drug for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if the drug is safe, helps shrink tumors, and improves quality of life.
Orange, CaliforniaAges 18 years+ - NCT07703878RecruitingPhase 1
A study of GS-1206 for people with solid tumors
This trial tests a new drug called GS-1206 for adults with solid tumors that have a specific genetic change. It aims to see if the drug is safe and can shrink or slow the growth of the cancer after other treatments have stopped working.
Grand Rapids, MichiganAges 18 years+ - NCT07693751RecruitingPhase 1/Phase 2
Testing a new drug for advanced colorectal cancer
This trial tests a new drug called SOT109 for people with advanced colorectal cancer that can't be removed by surgery or has spread. The goal is to see if it is safe, how well it works, and how the body handles it.
Houston, TexasAges 18 years+ - NCT07680582RecruitingEarly Phase 1
Personalized cancer vaccine after surgery for solid tumors
This trial tests a personalized vaccine designed to train your immune system to fight any remaining cancer cells after surgery or during standard therapy. It is for people with solid tumors who are stable and have no signs of disease getting worse.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07680764RecruitingPhase 2
Imzokitug plus pumitamig and chemo for first-line advanced lung cancer
This trial tests a new combination of drugs (imzokitug, pumitamig, and platinum-doublet chemotherapy) as a first treatment for advanced or metastatic non-small cell lung cancer that has not spread to the brain. The goal is to see if adding imzokitug makes the standard treatment work better.
Washington D.C., District of ColumbiaAges 18 years+ - NCT05435248RecruitingPhase 1/Phase 2
Study drug for advanced lung cancer with a specific EGFR change
This Phase 1/2 trial tests HS-10375, a study drug, in people with advanced or metastatic non-small-cell lung cancer (NSCLC) whose cancer has a specific EGFR mutation (C797S). It may help by targeting that mutation when standard treatments are not an option.
Guangzhou, GuangdongAges 18 years+ - NCT06674343RecruitingPhase 3
Furmonertinib for advanced lung cancer with EGFR mutations
This trial tests a higher dose of furmonertinib (160mg) as a first treatment for advanced non-small cell lung cancer that has specific EGFR mutations (19Del or L858R). It aims to see if this drug can help shrink tumors and delay disease progression.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07661641RecruitingPhase 1
Study of new radioactive treatments for GRPR-positive tumors
This early-phase study tests two new radioactive treatments (lutetium-177 and actinium-225) together with a guided imaging agent in people with GRPR-positive solid tumors (including prostate, breast, or colorectal cancers). The goal is to see if these treatments can shrink tumors that have stopped responding to standard therapies.
Melbourne N., VictoriaAges 18 years+ - NCT07661459RecruitingPhase 2
Antihistamine and aspirin with immunotherapy for solid tumors
This trial tests whether taking a daily antihistamine (like Claritin) and a daily aspirin alongside your immunotherapy can make the treatment work better. It's for people with solid tumors who are about to start a PD-1 or PD-L1 blocker.
Lexington, KentuckyAges 18–99 - NCT07641049RecruitingPhase 1
CAR-NK Cell Therapy for Advanced Prostate Cancer
This trial tests a new type of immune cell therapy (CAR-NK cells) designed to target and fight advanced prostate cancer that has stopped responding to hormone treatments. The cells are engineered to recognize and attack cancer cells that have specific markers (PSMA and PSCA) on their surface.
Shenzhen, GuangdongAges 18 years+ - NCT07635147Recruiting
Decision Support Tool for Advanced Breast Cancer
This study tests a digital tool designed to help patients with advanced (stage IV) breast cancer make treatment decisions. The tool may help you understand your options and feel more confident discussing them with your doctor.
Brooklyn, New YorkAges 18 years+ - NCT07629258RecruitingPhase 1
Testing GW01-200 tablets in advanced cancer patients
This is an early-stage trial testing a new drug called GW01-200 in people with advanced solid tumors or blood cancers that have gotten worse despite standard treatment. The study aims to find the right dose and see how well the drug works and is tolerated.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07561554RecruitingPhase 1
New BRAF-Targeting Drug for Advanced Solid Tumors
This is an early-stage study testing a new investigational drug (HSK42360-Na) designed to target a specific genetic mutation (BRAF V600) found in some advanced or metastatic cancers. The goal is to see if this drug is safe and effective for patients whose cancers have grown despite prior treatments.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07567846RecruitingPhase 1/Phase 2
GDC-1261 Safety and Activity in Advanced Prostate Cancer
This early-stage trial tests a new drug called GDC-1261 in men with advanced prostate cancer that has spread or gotten worse despite previous treatment. The study will look at whether the drug is safe and whether it helps slow or shrink the cancer.
Scottsdale, ArizonaAges 18 years+ - NCT06735391RecruitingPhase 3
JMT101 plus osimertinib vs osimertinib for EGFR-mutant lung cancer
This trial tests a new combination of two targeted drugs (JMT101 and osimertinib) against osimertinib alone for people with advanced lung cancer that has an EGFR mutation. The goal is to see if the combination works better as a first treatment.
GuangzhouAges 18 years+
Hear when a new Advanced or Metastatic Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for advanced or metastatic solid tumors?
- Yes. Clin2 currently lists 4,772 recruiting advanced or metastatic solid tumors studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a advanced or metastatic solid tumors trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a advanced or metastatic solid tumors trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Locally Advanced or Metastatic Solid Tumors
- Advanced/Metastatic Solid Tumors
- Locally Advanced (Unresectable) or Metastatic Solid Tumors
- Locally Advanced/Metastatic Solid Tumors
- Patients With Advanced Solid Tumors
- Mesothelin-positive Advanced Malignant Solid Tumors
- Recurrent or Metastatic Solid Tumors
- Advanced Solid Tumor
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.